Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 4Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Prostatic Neoplasms 2Neoplasm Metastasis 2Liver Neoplasms 2Glioblastoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Select Advanced Solid Tumors 1Sarcoma 1Recurrence 1Prostate Adenocarcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Glioma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1

Interventions

atezolizumab 1PROSTVAC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Prostate Adenocarcinoma × atezolizumab × Clear all
NCT04020094 2021-09-22

AtezoVax

University of Utah

Phase 2 Withdrawn
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡